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AbstrACt
Introduction In people with cystic fibrosis (CF), 
exacerbations have been shown to have profound and 
prolonged negative effects such as reducing physical 
activity and health-related quality of life, increasing the 
rate of decline of lung function and healthcare costs, and 
ultimately increasing the risk of mortality. Delayed initiation 
of treatment following the signs of an exacerbation has 
been shown to be associated with failure to recover to 
baseline. Therefore, the late identification and treatment 
of an exacerbation due to delayed presentation will 
potentially worsen short-term and long-term outcomes. 
We have developed a smartphone application, containing 
questions which require yes or no responses relating 
to symptoms suggestive of a respiratory exacerbation. 
Its use is intended to facilitate the early identification of 
symptoms suggestive of a respiratory exacerbation, and 
allow the CF team to initiate treatment sooner, thereby 
potentially reducing the risk of severe exacerbations which 
require intravenous antibiotics (IVAB) and often a hospital 
admission.
Methods We will undertake a randomised controlled trial. 
60 adults with CF will be recruited and randomised to 
either the intervention or control group. The intervention 
group will use the smartphone application weekly for 12 
months, or earlier than the next weekly reporting time 
if they feel their symptoms have worsened. The control 
group will continue to receive usual care, involving 
regular (approximately 3 monthly) CF outpatient clinic 
appointments. The primary outcome measure will be 
courses and days of IVAB.
Ethics and dissemination Approval was obtained from 
the Sir Charles Gairdner Group Human Research Ethics 
Committee for WA Health (2015-030) and Curtin University 
Human Research Ethics Committee (HR212/2015), 
and has been registered with the Australian and New 
Zealand Clinical Trials Registry. Results of this study will 
be presented at international conferences and published 
in peer-reviewed journals in accordance with the 
Consolidated Standards of Reporting Trials statement.
trial registration number ACTRN12615000599572.
IntroduCtIon
Cystic fibrosis (CF) is a disease characterised 
by periods of clinical stability, interspersed 
with periods of acute deterioration, known 
as exacerbations. Respiratory exacerbations 
have been shown to have profound and 
prolonged negative effects on people with 
CF, such as reducing physical activity1 and 
health-related quality of life (HRQoL),2 
increasing the rate of decline of lung func-
tion3 and healthcare costs,4 and ultimately 
increasing the risk of mortality.5 The decline 
in lung function may also contribute to 
increased feelings of depression.6 In people 
with CF, an exacerbation has been defined 
as a change in four or more disease-specific 
criteria comprising cough, sputum, haemop-
tysis, dyspnoea, fatigue, sinus pain and 
discharge, fever, worsening airflow obstruc-
tion (ie, reduced forced expiratory volume 
in 1 s (FEV1)), anorexia or weight loss, and 
changes in physical examination of the chest 
or chest radiography.7 
Of concern, of those individuals who expe-
rience an exacerbation requiring intravenous 
antibiotics (IVAB), approximately 25% have 
a persistent reduction in FEV1 at the end of 
their treatment,8 and more than half (58%) 
of these individuals do not regain their pre-ex-
acerbation level of FEV1 after 12 months.
8 
Delayed initiation of treatment has been 
shown to be associated with this failure to 
recover to baseline.8 Therefore, the late iden-
tification and treatment of an exacerbation 
strengths and limitations of this study
 ► This is the first long-term randomised controlled trial 
investigating a smartphone application for reporting 
symptoms in adults with cystic fibrosis.
 ► The pharmacist collecting primary outcome data, 
and the physicians prescribing intravenous antibiot-
ics, are blinded to the participants’ group allocation.
 ► Selecting questions to include in the smartphone 
application was difficult due to a lack of consensus 
of what defines an exacerbation in cystic fibrosis.
 ► It was not feasible to include spirometry in the in-
tervention in this study which may improve clinical 
interpretation of reported symptoms.
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due to delayed presentation will potentially worsen short-
term and long-term outcomes. People with CF may delay 
their presentation to a CF clinic for management of an 
exacerbation due to study, work or family commitments, 
the travel and financial burden involved in attending a CF 
clinic, a lack of understanding of the disease process or if 
affected by anxiety and depression.9
Telehealth has been evaluated in studies in people with 
CF using interventions such as monitoring of spirom-
etry,10–12 oxygen saturation10 13 and symptoms from 
home,10–12 using videoconferencing to measure exercise 
capacity14 and provide health assessment in the home,15 
and to provide routine outpatient clinics.16 Although 
telehealth, in the form of home monitoring, appears to 
be feasible and readily accepted by people with CF,17 to 
date, studies have not demonstrated a significant impact 
of telehealth on health outcomes such as exacerbation 
rates, lung function, HRQoL and healthcare utilisation 
(HCU). One reason for this may relate to the burden asso-
ciated with the telehealth interventions. That is, earlier 
work often required participants to record measure-
ments as often as daily and did not offer the opportunity 
to complete these measures outside the home (ie, there 
was no use of mobile technology), which compromised 
participant adherence to the telehealth intervention.
We aim to overcome this shortcoming by investigating 
the effects of using of an application for reporting symp-
toms that is completely mobile and stored on the partici-
pant’s own smartphone. This novel approach is intended 
to facilitate the early identification of symptoms suggestive 
of a respiratory exacerbation, and allow the CF team to 
initiate treatment sooner in the form of oral and inhaled 
antibiotics, and increased mucolytic therapy and airway 
clearance. This may potentially reduce the risk of severe 
exacerbations which require IVAB and often a hospital 
admission.
MEthods And AnAlysIs
This will be a prospective 12-month, single-blinded 
randomised controlled trial (RCT).
Participant screening and selection
Eligible participants will be identified by the principal 
investigator and recruited from routine outpatient 
clinic appointments at the adult CF centre at Sir Charles 
Gairdner Hospital (SCGH), Perth. The patient infor-
mation and consent form will be provided to potential 
participants, who will then be contacted by the principal 
investigator approximately 48 hours later to discuss their 
willingness to participate.
Inclusion criteria
Adults who meet the following criteria will be eligible 
to participate: diagnosis of CF; aged ≥18 years; under 
the care of the SCGH CF team; respiratory exacerba-
tion requiring treatment with IVAB in the preceding 12 
months; currently in a period of clinical stability defined 
as no signs of an exacerbation for the previous 2 weeks 
and able to understand written and spoken English.
Exclusion criteria
Criteria to exclude individuals from participating will be: 
previous lung transplantation or current listing for lung 
transplantation; inability to undertake a prescribed treat-
ment regimen or inability to use or not being in posses-
sion of a smartphone.
randomisation and allocation concealment
Participants will be randomly allocated to the interven-
tion or control group using the University of Sydney 
National Health Medical Research Council Clinical Trials 
Centre randomisation service. Recruitment will be strati-
fied according to gender, location (metropolitan vs rural 
and remote) and whether the participant is prescribed 
ivacaftor or lumacaftor/ivacaftor, as these medications 
can reduce the rate of exacerbations and improve lung 
function, weight and HRQoL.18 19
study measurements
Participants will have assessments performed at baseline 
(prior to randomisation), and at 6 and 12 months, unless 
otherwise stated. Assessments will be performed when the 
participant is in a period of clinical stability, defined as no 
signs of an exacerbation for the previous 2 weeks. If the 
participant has signs of an exacerbation at their sched-
uled follow-up time, the assessments will be completed at 
the subsequent visit when they are clinically stable. The 
principal investigator will perform all assessments during 
follow-up visits at SCGH. For telehealth assessments, 
spirometry and weight will be assessed by a health profes-
sional local to the participant, with the remainder of the 
assessments completed by the principal investigator.
Primary outcome
Number of courses of IVAB and IVAB days
Information regarding the use of IVAB will be obtained 
from the medical records of the participants by a pharma-
cist blinded to the study groups and verified against SCGH 
pharmacy dispensing records. This will be collected at the 
final assessment only.
secondary outcomes
Lung function (FEV1)
Lung function will be measured using a Medgraphics 
USB spirometer (MGC Diagnostics, Minnesota, USA) or 
Easyone spirometer (ndd Medical Technologies, Massa-
chusetts, USA). Each participant will perform up to eight 
maximal forced expiratory manoeuvres to ensure the two 
best attempts meet published standards.20
HRQoL: Cystic Fibrosis Questionnaire-Revised
This self-complete questionnaire comprises 50 questions 
answered on a 4-point Likert scale, and covers 12 domains 
comprising physical, vitality, emotion, treatment burden, 
health, social, body, role, weight, respiratory, digestion 
and eating.21 The Cystic Fibrosis Questionnaire-Revised 
 o
n
 20 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021136 on 21 April 2018. Downloaded from 
3Wood J, et al. BMJ Open 2018;8:e021136. doi:10.1136/bmjopen-2017-021136
Open Access
requires the user to recall information from the previous 
2 weeks.
Feelings of anxiety and depression: Hospital Anxiety and 
Depression Scale
The Hospital Anxiety and Depression Scale22 contains 
14 self-report questions, evenly divided into anxiety and 
depression scales (seven each). A 4-point Likert scale 
(0–3) is used to answer questions based on a recall period 
of 7 days.
Nutritional status: body mass index
Participants will have their height and weight measured, 
and body mass index (BMI) will be calculated.
Measures of HCU including time to first exacerbation requiring 
IVAB, oral and inhaled antibiotic use and cost, hospital admissions 
and cost, and number of CF clinic visits
At the final assessment only, the participant’s medical 
record will be reviewed to extract information pertaining 
to HCU. This includes: time (in days) from randomisa-
tion to the first exacerbation requiring IVAB; number of 
hospital admissions and days; number of courses and days 
of oral and inhaled antibiotics; number of CF clinic visits; 
estimated cost of IVAB and other antibiotic treatment; and 
estimated cost of hospital admissions. Costs related to HCU 
will be estimated using information provided from the 
SCGH Pharmacy and Finance departments. All potential 
participants receive their care at the SCGH CF centre or 
via shared care with an external respiratory physician (and 
not from a general practitioner). Prescribed antibiotic use 
will be well documented in the medical record, and partic-
ipants will not be required to keep a diary of antibiotic use. 
Non-clinical costs relating to participants’ travel, parking, 
time off work and telephone calls will not be recorded.
Medication adherence: Treatment Adherence Questionnaire-CF
Adherence to routine CF treatments will be assessed 
using the Treatment Adherence Questionnaire (TAQ-
CF).23 This measure has 12 treatment items and asks the 
user to report on the frequency of each treatment on 
a 7-point Likert scale (ranging from ‘not at all’ to ‘3 or 
more times per day’), and the duration of treatment on a 
6-point Likert scale (‘0’ to ‘25+’ min). The TAQ-CF also 
asks the participant to report on the barriers to individual 
treatments.
Absenteeism/presenteeism: WHO’s Health and Work Performance 
Questionnaire
Absenteeism is defined as being absent from work or 
study due to illness whereas presenteeism is defined as 
the loss of productivity associated with attending work or 
study when unwell.24 This questionnaire uses the absen-
teeism and presenteeism questions of the Health and 
Work Performance Questionnaire.25
System usability: System Usability Scale
The System Usability Scale26 is a validated assessment 
tool comprising 10 questions regarding the usability of 
technological systems, and is answered on a 5-point Likert 
scale. Other measures of system usability will include the 
time of day the smartphone application is used and how 
many times the questions were not completed.
Intervention
A smartphone application has been developed for use 
by participants to report symptoms on their own smart-
phones. The application contains 14 questions (box 1) 
that are required to be answered ‘yes’ or ‘no’. Twelve 
questions relate to respiratory symptoms; 10 questions 
are derived from the Fuchs exacerbation scale,7 with the 
addition of two symptoms (wheeze and chest tightness) 
commonly identified by adults with CF as indicators of an 
exacerbation27 and considered important by the research 
team. The application also asks the participant to answer 
two questions relating to their feelings of anxiety and 
depression. The data will then be transmitted securely 
via password-protected email to members of the research 
team. This smartphone application has demonstrated 
high system usability in people with CF, as well as good 
observer agreement between CF clinicians interpreting 
the data.28
Experimental group
Participants will be asked to use the smartphone appli-
cation once per week on a set day and time of their 
choosing, for a period of 12 months. A smartphone 
calendar alert will remind the participant to answer the 
symptom questions. Participants can also use the appli-
cation earlier than the next weekly reporting time if they 
feel their symptoms have worsened. If the participant 
misses one of their weekly reporting times, they will be 
prompted to answer the application questions via text 
message. If the participant responds ‘yes’ to any of the 
symptom questions, the principal investigator will alert 
the CF nurse practitioner, who will then phone the partic-
ipant to discuss their symptoms and whether treatment 
box 1 smartphone application questions (participants 
answer yes or no)
In the past week, have you had:
Worsening sputum volume or colour?
New or increased blood in your sputum?
Increased cough?
New or increased chest pain?
New or increased wheeze?
New or increased chest tightness?
Increased shortness of breath or difficulty breathing?
Increased fatigue or lethargy?
Fever?
Loss of appetite or weight?
Sinus pain or tenderness?
In the past week do you feel that your health has worsened?
In the past week, have you felt:
Low in mood?
Worried?
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(ie, oral or inhaled antibiotics) is required, in consulta-
tion with a CF physician blinded to the participant’s study 
group. The CF nurse practitioner will also determine if a 
formal review in the CF clinic is required. If the partici-
pant’s respiratory disease has been stable for 3 months, 
they will attend a routine CF clinic appointment.
Control group
Participants in this group will continue to receive usual 
care, involving routine CF clinic appointments (approxi-
mately 3 monthly). Participants can contact the CF Nurse 
Practitioner via telephone sooner if there is a change in 
their clinical status.
statistical analysis
Statistical analyses will be undertaken with Stata 
(StataCorp, Stata statistical Software Release: V.14) in 
accordance with the intention-to-treat principle. The 
distribution of data will be assessed for normality. A p 
value of <0.05 will be considered statistically significant. 
Negative binomial regression, and independent t-tests 
or Mann-Whitney U tests will be used to determine 
Figure 1 ‘Study design’. CF, cystic fibrosis.
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differences between the two groups. Further analyses 
will include general linear models to adjust for possible 
covariates.
Number of courses of IVAB and number of IVAB days
Summary statistics and frequencies will be provided for 
continuous and categorical variables. Descriptive plots 
will also be produced for all variables. Independent t-tests 
will be used to determine whether the number of courses 
of IVAB, and number of IVAB days, differs between the 
two groups. Further analyses will include general linear 
models to adjust for possible covariates including age, 
gender, BMI, Pseudomonas aeruginosa, pancreatic insuf-
ficiency and CF-related diabetes. Appropriate transfor-
mations will be conducted if the data are not normally 
distributed.
Other measurements
For all variables, a between-group analysis of these 
outcome measures will be performed using an indepen-
dent t-test (parametric data) or Mann-Whitney U test 
(non-parametric data). Within group changes in outcome 
measures collected at each visit will be assessed using 
one-way repeated measures analysis of variance (para-
metric data) or Friedman’s test (non-parametric data).
sample size calculations
This is a study comparing participants who will use a 
smartphone application and those who will not. To inves-
tigate the difference in the number of IVAB courses 
between the two groups, assuming a within group SD of 
1.21 (based on IVAB usage at the SCGH CF centre during 
the 2 years prior to the study), a sample size of 23 in each 
group will be required to detect a difference of one exac-
erbation requiring IVAB per participant, with 80% power 
and a significance level of p<0.05. To account for any loss 
to follow-up or drop-out, we will recruit an additional 
seven individuals per group for a total sample size of 60. 
No additional individuals are required to detect the same 
difference under non-parametric settings.
Patient and public involvement statement
The intervention used in this study was designed with 
input from participants in a pilot study conducted by the 
research team.28 There was no further involvement in the 
development of this RCT by patients or the public.
dAtA CollECtIon And MAnAgEMEnt
Participant data will not contain any information that 
allows the person’s identity to be known. All data stored 
electronically at SCGH will be kept on a password-pro-
tected computer or locked in a filing cabinet in the 
Department of Respiratory Medicine. Any printed infor-
mation including signed consent forms will be kept in 
locked filing cabinets. Data will be kept for a minimum 
of 15 years. After this time, data collection forms will be 
shredded and electronic files will be deleted.
Data transmitted from the smartphone application 
will be transmitted securely via password-protected 
email to members of the research team at SCGH, and 
not kept in ‘cloud’ storage at any stage. After transmis-
sion from the participant’s phone or tablet, the data 
will be automatically deleted, preventing any poten-
tial breach of privacy if the device is lost or stolen. The 
application will also request the user to enter a unique, 
four-digit passcode before being able to access the 
application questions.
EthICs
 This trial has been registered with the Australian and New 
Zealand Clinical Trials Registry (ACTRN12615000599572). 
Results of this study will be presented at international 
conferences and published in peer-reviewed journals in 
accordance with the Consolidated Standards of Reporting 
Trials statement (figure 1).29
dIsCussIon
This will be the first RCT investigating the impact of 
a smartphone application used by people with CF to 
report symptoms suggestive of a respiratory exacerbation 
directly to the CF team. By reducing the delay often seen 
in the reporting of symptoms, and therefore facilitating 
the earlier provision of treatment, the severity of exacer-
bations and the need for IVAB and hospital admissions 
may be reduced.
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